StonvexLoading…
StonvexStonvexStonvexCore line items from CTAS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-05-31 | Annual 2024 2024-05-31 | Annual 2023 2023-05-31 | Annual 2022 2022-05-31 |
|---|---|---|---|---|
Revenue | $10.34B | $9.60B | $8.82B | $7.85B |
Operating Income | $2.36B | $2.07B | $1.80B | $1.59B |
Net Income | $1.81B | $1.57B | $1.35B | $1.24B |
EPS (Diluted) | $4.40 | $3.79 | $3.25 | $11.65 |
Total Assets | $9.83B | $9.17B | $8.55B | $8.15B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $263.97M | $342.01M | $124.15M | $90.47M |
Free Cash Flow OCF − CapEx | $1.76B | $1.66B | $1.26B | $1.30B |
Shares Outstanding | 402.95M | 405.01M | 101.73M | 101.71M |